And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...
Ziihera is one of several variations of the bispecific antibody Zanidatamab that Zymeworks developed for treating various types of cancer, and one of three in the advanced “pivotal” trial phase.
The bispecific antibody is currently under FDA priority review for biliary tract cancer, with a target action date of Nov. 29. If approved, Zymeworks (NASDAQ:ZYME) is set to receive milestone ...
Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with ...
Zymeworks, Inc. is a biopharmaceutical company ... Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor ...
Zymeworks Inc is a clinical-stage biopharmaceutical ... Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase ...
This event, led by Paul Moore, PhD, Zymeworks’ Chief Scientific Officer, will feature: Updates on our portfolio of solid tumor targeting antibody-drug conjugates and T-cell Engager (TCE ...
Don't Miss our Black Friday Offers: Zymeworks has achieved a significant milestone with the FDA’s accelerated approval of Ziihera, a dual HER2-targeted bispecific antibody for HER2-positive ...
It is on track to possibly reach this goal because, in a prior phase 2 study, it was shown that patients who took this HER2 bi-specific antibody from Zymeworks had a median PFS rate of 12 months ...